Stefano Luzzago

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6880288/publications.pdf

Version: 2024-02-01

115	1,258	471509	526287
papers	citations	17 h-index	27 g-index

118	118	118	1707
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radiomics in prostate cancer: an up-to-date review. Therapeutic Advances in Urology, 2022, 14, 175628722211090.	2.0	62
2	Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. Journal of Endourology, 2018, 32, 257-263.	2.1	51
3	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. European Urology, 2015, 68, 777-784.	1.9	48
4	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunology, Immunotherapy, 2021, 70, 265-273.	4.2	44
5	Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients. Urologia Internationalis, 2019, 102, 43-50.	1.3	43
6	Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer and Prostatic Diseases, 2016, 19, 63-67.	3.9	41
7	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. Surgical Oncology, 2020, 32, 8-13.	1.6	39
8	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. Clinical Genitourinary Cancer, 2015, 13, 562-567.	1.9	37
9	In-hospital length of stay after major surgical oncological procedures. European Journal of Surgical Oncology, 2018, 44, 969-974.	1.0	34
10	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). European Radiology, 2021, 31, 716-728.	4.5	31
11	Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. European Urology Focus, 2021, 7, 644-652.	3.1	28
12	Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 31-37.	3.9	26
13	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urology and Nephrology, 2021, 73, 442-451.	2.5	23
14	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologistsâ€™ Training Program?. Clinical Genitourinary Cancer, 2019, 17, 88-96.	1.9	22
15	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 76.e1-76.e9.	1.6	22
16	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. BJU International, 2020, 126, 104-113.	2.5	21
17	Prognostic role of the systemic immuneâ€“inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Cancer Immunology, Immunotherapy, 2021, 70, 2641-2650.	4.2	21
18	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. European Urology Focus, 2016, 2, 86-91.	3.1	20

#	Article	IF	Citations
19	Contemporary conditional cancerâ€specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. Journal of Surgical Oncology, 2020, 121, 1154-1161.	1.7	20
20	Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. European Urology Focus, 2019, 5, 636-641.	3.1	19
21	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. Urologia Internationalis, 2018, 101, 56-64.	1.3	17
22	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e602-e611.	1.9	17
23	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e15-59.e22.	1.6	16
24	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	2.5	16
25	Thuliumâ€“yttriumâ€“aluminiumâ€“garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. World Journal of Urology, 2018, 36, 265-270.	2.2	15
26	Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center. Cancers, 2020, 12, 1183.	3.7	15
27	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. World Journal of Urology, 2021, 39, 461-472.	2.2	15
28	Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?. Clinical and Translational Oncology, 2021, 23, 1717-1726.	2.4	15
29	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. Clinical Genitourinary Cancer, 2017, 15, 67-71.	1.9	14
30	Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. Cancer Epidemiology, 2020, 67, 101762.	1.9	14
31	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmetteâ€“Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	2.6	14
32	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 537-544.	1.6	13
33	Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison Between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder. Journal of Endourology, 2021, 35, 151-158.	2.1	13
34	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. Diagnostics, 2021, 11, 355.	2.6	12
35	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. Urology, 2016, 88, 97-103.	1.0	11
36	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. Clinical Genitourinary Cancer, 2020, 18, 129-137.e3.	1.9	11

#	Article	IF	Citations
37	A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients. Cancers, 2020, 12, 1513.	3.7	11
38	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. European Urology Open Science, 2021, 27, 19-28.	0.4	11
39	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in Oncology, 2021, 11, 651745.	2.8	11
40	A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 431.e15-431.e22.	1.6	11
41	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e610-e618.	1.9	10
42	PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. World Journal of Urology, 2021, 39, 787-796.	2.2	10
43	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e1-236.e7.	1.6	10
44	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Nonâ€“clear Cell Renal Cell Carcinoma Patients. European Urology Focus, 2021, 7, 598-607.	3.1	10
45	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. World Journal of Urology, 2020, 38, 2819-2826.	2.2	10
46	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 395-401.	1.9	9
47	The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes and Control, 2020, 31, 283-290.	1.8	9
48	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. Cancer Causes and Control, 2020, 31, 263-272.	1.8	9
49	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naÃ¯ve patients: follow-up of a PRECISION trial-like retrospective cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 406-413.	3.9	9
50	The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. European Journal of Surgical Oncology, 2017, 43, 808-814.	1.0	8
51	Pathological findings at radical prostatectomy of biopsy naÃ¯ve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 929.e11-929.e19.	1.6	8
52	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. European Journal of Surgical Oncology, 2020, 46, 1347-1352.	1.0	8
53	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	1.6	8
54	Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1492-1499.	4.9	8

#	Article	IF	Citations
55	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	2.5	8
56	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	2.5	8
57	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. European Journal of Surgical Oncology, 2021, 47, 463-469.	1.0	7
58	Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy. Clinical Genitourinary Cancer, 2021, 19, e335-e345.	1.9	7
59	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. Journal of Surgical Oncology, 2019, 120, 1266-1275.	1.7	6
60	Prostate cancer characteristics and cancer-specific mortality of Native American patients. Prostate Cancer and Prostatic Diseases, 2020, 23, 277-285.	3.9	6
61	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. Clinical Genitourinary Cancer, 2020, 18, 117-128.e5.	1.9	6
62	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 600-607.	2.1	6
63	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. World Journal of Urology, 2021, 39, 813-822.	2.2	6
64	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. Cancers, 2021, 13, 3278.	3.7	6
65	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1340-1347.	4.9	6
66	A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. Asian Journal of Andrology, 2022, 24, 579.	1.6	6
67	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. Clinical Genitourinary Cancer, 2017, 15, e223-e228.	1.9	5
68	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology, 2018, 1, 268-275.	5.4	5
69	Medical Expulsive Therapy for Symptomatic Distal Ureter Stones: Is the Combination of Bromelain and Tamsulosin More Effective than Tamsulosin Alone? Preliminary Results of a Single-Center Study. Urologia Internationalis, 2019, 102, 145-152.	1.3	5
70	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. Clinical Genitourinary Cancer, 2020, 18, e450-e456.	1.9	5
71	Bladder cancer incidence rates and trends in young adults aged 20-39 years. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 934.e11-934.e19.	1.6	5
72	Rates of otherâ€cause mortality after radical cystectomy are decreasing over timeâ€"A populationâ€based analysis over two decades. Journal of Surgical Oncology, 2020, 121, 1329-1336.	1.7	5

#	Article	IF	Citations
73	Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. Integrative Cancer Therapies, 2021, 20, 153473542110194.	2.0	5
74	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 609-619.	1.4	5
75	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 239.e1-239.e7.	1.6	5
76	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 880-888.	1.3	5
77	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. World Journal of Urology, 2019, 37, 1329-1337.	2.2	4
78	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. Prostate Cancer and Prostatic Diseases, 2020, 23, 94-101.	3.9	4
79	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 506-514.	1.6	4
80	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. Surgical Oncology, 2021, 36, 131-137.	1.6	4
81	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, 51, 1149-1157.	1.3	4
82	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	1.3	4
83	Robot-Assisted Intracorporeal Orthotopic Ileal Neobladder: Description of the â€œShellâ€•Technique. Journal of Clinical Medicine, 2021, 10, 3601.	2.4	4
84	Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 74.e1-74.e7.	1.6	4
85	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU International, 2022, 129, 524-533.	2.5	4
86	The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. Applied Sciences (Switzerland), 2022, 12, 2268.	2.5	4
87	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	1.6	3
88	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 567-574.	1.3	3
89	Robot-assisted inguinal lymphadenectomy: preliminary experience and perioperative outcomes from an Italian referral center. Therapeutic Advances in Urology, 2020, 12, 175628722091338.	2.0	3
90	Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?. BJU International, 2021, 127, 454-462.	2.5	3

#	Article	IF	Citations
91	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	2.2	3
92	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	2.2	3
93	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. Minerva Urology and Nephrology, 2021, , .	2.5	3
94	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. Clinical Genitourinary Cancer, 2020, 18, 35-44.e1.	1.9	2
95	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. Scandinavian Journal of Urology, 2020, 54, 382-386.	1.0	2
96	Minimally invasive versus open radical cystectomy: long term oncologic outcomes compared. Translational Andrology and Urology, 2020, 9, 1006-1008.	1.4	2
97	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. Urology, 2020, 140, 91-97.	1.0	2
98	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. Surgical Oncology, 2021, 37, 101519.	1.6	2
99	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. Frontiers in Oncology, 2021, 11, 732766.	2.8	2
100	Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 736.e1-736.e7.	1.6	2
101	MP77-16 FIRST REPEATED BIOPSY REPRESENTS THE MOST INFORMATIVE PREDICTOR OF PROGRESSION-FREE SURVIVAL AT 3 YEARS FOLLOW-UP IN PATIENTS INCLUDED IN AN ACTIVE SURVEILLANCE PROTOCOL FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	1
102	Assessment of otherâ€cause mortality in localized renal cell carcinoma patients within 15 years: A populationâ€based analysis. Journal of Surgical Oncology, 2020, 122, 1506-1513.	1.7	1
103	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1â€“4Âcm renal cell carcinomas. Cancer Causes and Control, 2021, 32, 119-126.	1.8	1
104	MP4-16 PATTERNS OF CLINICAL RECURRENCE AND IMPACT OF SITEÂOFÂMETASTASIS ON MORTALITY OF PATIENTS WITH NODEÂPOSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2015, 193, .	0.4	0
105	MP72-04 IMPACT OF THE SITE OF RECURRENCE AFTER RADICAL CYSTECTOMY ON SURVIVAL: DIFFERENT SITES FOR DIFFERENT OUTCOMES.. Journal of Urology, 2015, 193, .	0.4	0
106	MP82-03 SALVAGE LYMPH NODE DISSECTION FOR CLINICALLY RECURRENT PROSTATE CANCER: WHICH PATIENTS DO BENEFIT FROM THIS APPROACH?. Journal of Urology, 2015, 193, .	0.4	0
107	PD33-02 VARIANT HISTOLOGIC DIFFERENTIATION IN BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: INCIDENCE AND LONG TERM SURVIVAL IN A SINGLE INSTITUTION STUDY.. Journal of Urology, 2016, 195, .	0.4	0
108	MP63-11 PREOPERATIVE PLATELET TO LYMPHOCYTE RATIO AS A PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY DUE TO BLADDER CANCER. Journal of Urology, 2016, 195, .	0.4	0

#	Article	IF	Citations
109	PD33-10 THE PRESENCE OF RESIDUAL CARCINOMA IN SITU ALONE (PTIS) IN PATIENTS TREATED WITH RADICAL CYSTECTOMY DOES NOT AFFECT LONG TERM RECURRENCE AND SURVIVAL RATES. Journal of Urology, 2016, 195, .	0.4	0
110	MP14-06 THE IMPACT OF ADJUVANT RADIOTHERAPY ON CANCER-SPECIFIC MORTALITY IN PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVOLVEMENT: A COMPETING-RISKS REGRESSION ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0
111	MP77-20 MULTIPARAMETRIC MRI REPRESENTS AN ADDED VALUE BUT NOT A SUBSTITUTE OF FOLLOW-UP BIOPSIES IN PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
112	MP58-09 PREDICTING LOCAL FAILURE AFTER RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS: IMPLICATIONS FOR THE SELECTION OF CANDIDATES AT ADJUVANT RADIATION THERAPY. Journal of Urology, 2017, 197, .	0.4	0
113	PD51-11 PATHOLOGICAL FINDINGS AT RADICAL PROSTATECTOMY AFTER INITIAL ACTIVE SURVEILLANCE IN LOW-RISK PROSTATE CANCER PATIENTS. DID WE MISS THE CHANCE TO CURE?. Journal of Urology, 2017, 197, .	0.4	0
114	Uro-oncologic patient management during theÂCOVID-19 pandemic: survey findings fromÂan Italian oncologic hub. Future Oncology, 2021, 17, 3615-3625.	2.4	0
115	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	2.2	0